Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immunoconjugate Therapy in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

NCT04491370 is registered in ClinicalTrials.gov with New York Medical College as lead sponsor.

NCT NCT04491370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04491370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immunoconjugate Therapy in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Lead sponsor
New York Medical College
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 1, 2021
Completion date
August 15, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, burkitt lymphoma, diffuse large b cell lymphoma, follicular lymphoma, hodgkin lymphoma, mantle cell lymphoma, marginal zone lymphoma, richter syndrome, transformed non-hodgkin lymphoma